Klotho Neurosciences Finalizes Shareholder Vote on Reverse Split to Avoid Delisting, Proposes Significant Equity Plan Expansion

summarizeSummary

Klotho Neurosciences has filed its definitive proxy statement, setting the terms for a shareholder vote on a reverse stock split to maintain Nasdaq listing and a substantial increase in its equity incentive plan, which could lead to significant dilution.

check_boxKey Events

• Reverse Stock Split Proposal

  Shareholders will vote on a reverse stock split with a ratio between one-for-2 and one-for-50, aimed at increasing the per-share price to meet Nasdaq's $1.00 minimum bid requirement and avoid delisting.

• Equity Incentive Plan Expansion

  The company seeks to increase the shares available under its 2024 Equity Incentive Plan to 10,000,000, representing a potential dilution of approximately 13.3% of current outstanding shares, to attract and retain key personnel.

• Special Meeting Scheduled

  A virtual Special Meeting of Stockholders is scheduled for February 13, 2026, to vote on these critical proposals.

auto_awesomeAnalysis

This definitive proxy statement (DEF 14A) finalizes the terms for a special meeting of stockholders, following the preliminary proxy (PRE 14A) filed on January 12, 2026. The company is seeking approval for a reverse stock split, with a wide ratio range of one-for-2 to one-for-50, primarily to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This is a critical measure to avoid potential delisting. Additionally, shareholders will vote on a substantial amendment to the 2024 Equity Incentive Plan, increasing the shares reserved for issuance to 10,000,000. This represents a significant potential dilution of approximately 13.3% of current outstanding shares, which could impact existing shareholder value. The necessity of these actions highlights the company's challenges in maintaining its listing and attracting talent, making this a very important filing for investors.